

8/16/04

Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/722,702
Filing Date	25-Nov-2003
First Named Inventor	Elfatih Elsein
Art Unit	1623
Examiner Name	
Attorney Docket Number	01-0157-CIP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T
m		WO 00/78777	December 28, 2000	PCT	_____	_____	
		WO 00/78778	December 28, 2000	PCT	_____	_____	
m		WO 00/78779	December 28, 2000	PCT	_____	_____	

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
m		KLOTZ et al: "2-Substituted N-Ethylcarboxamidoadenosine Derivatives as High-Affinity Agonists at Human A3 Adenosine Receptors", Naunyn-Schmiedeberg's Archives of Pharmacology, Springer, Berlin, DE., Vol. 360, no. 2, 1999, pages 103-108 XP000984051, ISSN: 0028-1298, compound 8, tables 1,2	
m		BARALDI et al: "Novel N6-(Substituted-phenylcarbonyl) Adenosine-5'-Uronamides as Potent Agonist for A2 Adenosine Receptors", Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 39, no. 3, February 1996 (1996-02), pages 802-806, XP002913657, ISSN: 0022-2623, conclusions on page 804, pages 803, column 2, paragraph 4	

Examiner Signature	<i>d/khane</i>	Date Considered	11/10/05
--------------------	----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/722,702
Filing Date	25-Nov-2003
First Named Inventor	Elfatih Elsein
Art Unit	1623
Examiner Name	
Attorney Docket Number	01-0157-CIP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T
dl		WO 00/78777	December 28, 2000	PCT	 	 	
		WO 00/78778	December 28, 2000	PCT	 	 	
dl		WO 00/78779	December 28, 2000	PCT	 	 	

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
dl		KLOTZ et al: "2-Substituted N-Ethylcarboxamidoadenosine Derivatives as High-Affinity Agonists at Human A3 Adenosine Receptors", Naunyn-Schmiedeberg's Archives of Pharmacology, Springer, Berlin, DE., Vol. 360, no. 2, 1999, pages 103-108 XP000984051, ISSN: 0028-1298, compound 8, tables 1,2	
dl		BARALDI et al: "Novel N6-(Substituted-phenylcarbamoyl) Adenosine-5'-Uronamides as Potent Agonist for A2 Adenosine Receptors", Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 39, no. 3, February 1996 (1996-02), pages 802-806, XP002913657, ISSN: 0022-2623, conclusions on page 804, pages 803, column 2, paragraph 4	

Examiner Signature	<i>dl Elsein</i>	Date Considered	11/10/05
--------------------	------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.